文献速递抗栓抗凝管理药物不良反应与药物警戒

经导管主动脉瓣置换术后的抗栓选择

Antithrombotic selection in patients undergoing transcatheter aortic valve replacement.
PubMed 文献 · Am J Health Syst Pharm · 2021-01-01

本文讨论经导管主动脉瓣置换术(TAVR)后最适抗栓方案的临床争议。综述现有证据、指南与推荐意见,指出无抗凝指征者单联抗血小板治疗可减少出血而不牺牲缺血保护;有抗凝指征者华法林联合单联抗血小板优于三联抗栓,华法林单药出血更少。直接口服抗凝药中阿哌沙班在合并房颤者中显示安全有效,而利伐沙班常规使用增加不良心脏与出血事件。现有证据与指南对TAVR后抗栓选择缺乏共识,需结合患者个体因素与合并症权衡血栓与出血风险。

要点

  • 无抗凝指征者,单联抗血小板治疗较双联减少出血且不牺牲缺血保护。
  • 有抗凝指征者,华法林联合单联抗血小板优于三联抗栓,华法林单药出血进一步减少。
  • 阿哌沙班在合并房颤者中安全有效,利伐沙班常规使用增加不良事件。

核心结论

  • 现有证据与指南对TAVR后抗栓选择缺乏共识。
  • 需根据患者个体因素与合并症权衡血栓与出血风险来制定方案。

研究设计与样本

  • 本文为综述,讨论TAVR后抗栓治疗的现有证据、指南与推荐意见。

主要发现

  • 无抗凝指征者,早期试验采用双联抗血小板作为术后首选,较新研究提示单联抗血小板减少出血且不牺牲缺血保护。
  • 有抗凝指征者,华法林联合单联抗血小板较三联抗栓提供相似缺血保护并减少临床显著出血。
  • 华法林单药与出血事件进一步减少相关。
  • 一项试验显示阿哌沙班在合并房颤者中安全有效;利伐沙班常规使用增加不良心脏与出血事件,直接口服抗凝药效用存疑。

临床怎么用

  • 无长期抗凝指征者优先考虑单联抗血小板治疗。
  • 有抗凝指征者避免三联抗栓,优先华法林联合单联抗血小板或华法林单药。
  • 合并房颤者可考虑阿哌沙班,避免常规使用利伐沙班。
  • 制定方案时个体化评估血栓与出血风险及合并症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Clinical controversy regarding the most appropriate antithrombotic regimen after transcatheter aortic valve replacement remains. Current evidence, guidelines, and recommendations are discussed. SUMMARY: Antithrombotic selection following transcatheter aortic valve replacement depends on a variety of patient-specific factors. For patients without a preexisting indication for anticoagulation, initial trials employed dual antiplatelet therapy as the postprocedural therapy of choice. Newer studies in this patient population, however, suggest single antiplatelet therapy reduces bleeding events without sacrificing ischemic protection. In patients with a preexisting indication for anticoagulation, warfarin plus single antiplatelet therapy, as opposed to triple antithrombotic therapy, offered similar ischemic protection while reducing clinically significant bleeding. Warfarin monotherapy was associated with a further reduction in bleeding events. One trial demonstrated the safety and efficacy of using apixaban in patients with concomitant atrial fibrillation; however, routine use of rivaroxaban increased adverse cardiac and bleeding events, leaving the utility of direct-acting oral anticoagulants in question. CONCLUSION: Available evidence and current guidelines point to a lack of consensus regarding antithrombotic selection after transcatheter aortic valve replacement. Patient-specific factors and comorbidities must be considered when tailoring therapy, with an emphasis on balancing thrombotic and bleeding risks.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Lai JK, Willenborg KL, Berei T, et al. Antithrombotic selection in patients undergoing transcatheter aortic valve replacement. Am J Health Syst Pharm. 2021. PMID: 33119752. doi:10.1093/ajhp/zxaa329

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。